穴位贴敷治疗社区患者肺部感染发热的效果

目的　探究穴位贴敷治疗社区患者肺部感染发热的疗效。方法　选择2018年9月至2019年9月，广州市海珠区江海街社区卫生服务中心肺部感染发热患者100例，依据不同治疗干预方式随机分为观察组与对照组。观察组50例，男31例，女19例，年龄31～75（48.24±6.73）岁，进行穴位贴敷治疗干预（自拟中药方实施穴位贴敷治疗，1次/d）；对照组50例，男33例，女17例，年龄32～74（48.19±6.71）岁，给予常规西药治疗（乙酰氨基酚片，1 次/d）。比较分析两组间的临床疗效、血清炎症因子水平、不良反应等情况。计数资料采用χ²检验，计量资料采用t检验，用率（%）和（x±s）表示。结果　观察组的血清降钙素原（PCT）水平、白细胞介素-18（IL-18）、白细胞介素-6 （IL-6）、超敏C反应蛋白（hs-CRP）指标分别为（1.64±0.52）μg/L、（48.12±11.35）mg/L、（9.75±3.38）mg/L、（5.12±1.70）mg/L，均明显低于对照组［（5.85±2.49）μg/L、（95.53±21.25）mg/L、（18.69±6.18）mg/L、（9.58±3.89）mg/L］，差异均有统计学意义（t=11.703、13.915、8.974、7.428，均P<0.05）。观察组头晕、呕吐、皮肤瘙痒发生率为2.00%（1/50），明显低于对照组［16.00%（8/50）］，差异有统计学意义（χ²=5.982，P<0.05）。观察组对疾病的治疗总有效率为96.00%（48/50），明显高于对照组［70.00%（35/50）］，差异有统计学意义（χ²=11.977，P<0.05）。观察组的症状改善时间短于对照组，观察组为（5.12±1.35） d，对照组为（6.33±1.13） d，差异有统计学意义（t=3.874，P<0.05）。结论　针对社区肺部感染发热患者，在临床上给予患者穴位贴敷治疗干预的方式，将促进患者疾病快速恢复，降低不良反应的发生率，安全性较高，能明显改善患者的血清炎症因子水平，具有临床应用价值。

Acupoint application for community patients with fever caused by pulmonary infection

Objective　To explore the efficacy of acupoint application in the treatment of community patients with fever caused by pulmonary infection. Methods　One hundred patients with fever caused by pulmonary infection treated at Health Service Center of Jianghai Street Community from September 2018 to September 2019 were selected, and were divided into an observation group and a control group according to the intervention methods, with 50 cases in each group. There were 31 males and 19 females in the observation group, and they were 31-75 (48.24±6.73) years old. There were 33 males and 17 females in the control group, and they were 32-74 (48.19±6.71) years old. The observation group used self-made acupoint application of Chinese medicine once per day, and the control group took acetaminophen tablets once per day. The clinical efficacies, serum inflammatory factor levels, and adverse reactions between the two groups were compared and analyzed. The enumeration and measurement data were expressed as rate (%) and (x±s), and were compared by χ² and t tests, respectively,. Results　The levels of procalcitonin (PCT), interleukin 18 (IL-18), interleukin 6 (IL-6), and hypersensitive C-reactive protein (hs-CRP) were (1.64±0.52) μg/L, (48.12±11.35) mg/L, (9.75±3.38) mg/L, and (5.12±1.70) mg/L in the observation group, and were (5.85±2.49) μg/L, (95.53±21.25) mg/L, (18.69±6.18) mg/L, and (9.58±3.89) mg/L in the control group, with statistical differences (t=11.703, 13.915, 8.974, and 7.428; all P<0.05). The incidence of dizziness, vomiting, and skin pruritus was 2.00% (1/50) in the observation group, and was 16.00% (8/50) in the control group, with a statistical difference (χ²=5.982, P<0.05). The total effective rate was 96.00% (48/50) in the observation group, and was 70.00% (35/50) in the control group, with a statistical difference (χ²=11.977, P<0.05). The symptom improvement time was (5.12±1.35) d in the observation group, and was (6.33±1.13) d in the control group, with a statistical difference (t=3.874, P<0.05). Conclusion　Acupoint application for community patients with fever caused by pulmonary infection can improve their recovery and levels of serum inflammatory factors and reduce the incidence of adverse reactions and is safe, with clinical application value.